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A B S T R A C T
Background: Data on antimicrobial use among hospitalized children in Africa are very limited due to the
absence of electronic prescription tracking.
Methods: This study evaluated antimicrobial consumption rates, the antimicrobial spectrum used, and
the indications for therapy on a paediatric ward and in the paediatric intensive care unit (PICU) at
Tygerberg Hospital, Cape Town, South Africa. Antimicrobial prescription and patient demographic data
were collected prospectively from May 10, 2015 to November 11, 2015. For the same period, data on
antimicrobials dispensed and costs were extracted from the pharmacy electronic medicine management
system. The volume of antimicrobials dispensed (dispensing data) was compared with observed
antimicrobial use (prescription data).
Results: Of the 703 patients admitted, 415/451 (92%) paediatric ward admissions and 233/252 (92%) PICU
admissions received 1 antimicrobials. On the ward, 89% of prescriptions were for community-acquired
infections; 29% of PICU antimicrobials were prescribed for healthcare-associated infections. Ampicillin
and third-generation cephalosporins were the most commonly prescribed agents. Antimicrobial costs
were 67 541 South African Rand (ZAR) (5680 United States Dollars (USD)) on the ward and 210 484 ZAR
(17 702 USD) in the PICU. Ertapenem and meropenem were the single largest contributors to
antimicrobial costs on the ward (43%) and PICU (30%), respectively. The volume of antimicrobials
dispensed by the pharmacy (dispensing data) differed considerably from observed antimicrobial use
(prescription data).
Conclusions: High rates of antimicrobial consumption were documented. Community-acquired infections
were the main indication for prescription. Although pharmacy dispensing data did not closely
approximate observed use, this represents a promising method for antimicrobial usage tracking in the
future.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier .com/ locate / i j idIntroduction
Antimicrobial overuse is an important contributor to the
development of antimicrobial resistance worldwide. Antimicrobial
consumption is particularly high among paediatric inpatients
owing to a predominance of infectious pathologies (both
community- and healthcare-associated infection) and non-speciﬁc
disease presentations, with difﬁculty in excluding bacterial
infections. Few studies have assessed the appropriateness of* Corresponding author.
E-mail address: dramowski@sun.ac.za (A. Dramowski).
https://doi.org/10.1016/j.ijid.2018.05.020
1201-9712/© 2018 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).antimicrobial use in children, but in high-income settings,
antimicrobial prescribing errors occur frequently, including incor-
rect dosing, inappropriate antimicrobial choice, no indication for
therapy, inadequate treatment duration, and inappropriate route
of administration (Blinova et al., 2013; Newland et al., 2012;
Kreitmeyr et al., 2017).
A recent point prevalence study (Antibiotic Resistance and
Prescribing in European Children – ARPEC) surveyed 17 693
paediatric inpatients in 41 countries, including six African
hospitals (Versporten et al., 2013). Bacterial lower respiratory
tract infections were the most common indication for antimicro-
bial prescription worldwide. At the six African hospitals studied,
gentamicin and ceftriaxone were the most commonly prescribedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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antimicrobial usage. In an Ethiopian paediatric inpatient setting,
gentamicin (26%) and ceftriaxone (44%) were also identiﬁed as
the most commonly prescribed antimicrobials (Feleke et al.,
2013). In the ARPEC study, 37% of all paediatric inpatients had one
or more antimicrobials prescribed; the highest antimicrobial use
rates (61%) were documented in paediatric intensive care units
(PICU). Other international studies have conﬁrmed high antimi-
crobial usage rates (ranging from 32% to 70%) (Grohskopf et al.,
2005; Amadeo et al., 2010; Gandra et al., 2017; De Luca et al.,
2016), with the highest paediatric inpatient antimicrobial
consumption rates reported from African countries: Mozambique
(98%), Botswana (72%), Ethiopia (98%), and Ghana (69%)
(Monteiro et al., 2017; Labi et al., 2018; Fisher et al., 2009;
Alemnew and Atnaﬁe, 2015).
A speciﬁc challenge to monitoring and reporting paediatric
antimicrobial consumption data is the lack of a standardized usage
deﬁnition. Among adult patients, consumption patterns can be
easily compared using the deﬁned daily dose (DDD) for each
antimicrobial agent (total grams of the drug divided by the number
of grams in an average adult daily dose) (WHO, 2018). This method
cannot be applied accurately to paediatric populations as
antimicrobial dosage in children is based on body weight or body
surface area.
Accurate and ongoing measurement of local antimicrobial
consumption patterns helps stewardship teams set program-
matic targets and assess the impact of interventions. Many high-
income countries use electronic laboratory and pharmacy
surveillance systems to measure usage trends and generate
real-time/early warning systems for infectious disease out-
breaks, supporting antimicrobial stewardship efforts. However,
in resource-limited healthcare settings and particularly  in
Africa, surveillance of antimicrobial use through electronic
prescribing is generally unavailable (Rattanaumpawan et al.,
2017). Furthermore, the lack of electronic prescription tracking
means that any antimicrobial consumption data must be
collected manually, which is labour-intensive and more prone
to error. The lack of tools for antimicrobial consumption
monitoring hampers the publication of data on paediatric
antimicrobial use from low- and middle-income countries
(LMIC) (Dillon et al., 2014).
Although electronic prescribing is not available, electronic
pharmacy stock management tools are widely used in public
sector South African healthcare facilities. The potential use of
electronic dispensing data for tracking antimicrobial usage
trends is appealing, as it avoids the need for labour-intensive
prescription audits. However, pharmacy dispensing data may
not always accurately reﬂect usage data; for example, in low-
resource neonatal/paediatric settings, the sharing of multi-dose
antimicrobial vials between patients is a common practice. In
such cases, dispensing data would only reﬂect the initial patient
to whom the antimicrobial was dispensed and not the
subsequent patients.
Given the paucity of data on antimicrobial use in Africa, this
study was performed to evaluate antimicrobial consumption on
two paediatric wards, comparing prescription chart audit data
with pharmacy dispensing data at Tygerberg Hospital, Cape Town,
South Africa.
Methods
Study setting
Tygerberg Hospital in Cape Town, South Africa is a large 1384-
bed academic complex, including 300 neonatal/paediatric beds
and 17 000 neonatal/paediatric (0–14 years) admissions annually.There are 13 children’s wards: medical generalist wards, medical
specialist wards, surgical wards, neonatal wards, and two intensive
care units – neonatal and paediatric (PICU). Community-acquired
infectious (CAI) diseases like human immunodeﬁciency virus
(HIV), tuberculosis (TB), respiratory tract infections, and gastroen-
teritis are common indications for paediatric hospitalization. The
treatment of paediatric healthcare-associated infections (HAI) is
also a major contributor to antimicrobial use on the wards
(Dramowski et al., 2016). The hospital implemented a formal
antimicrobial stewardship programme in 2014 with annual
antimicrobial use point prevalence surveys, weekly antimicrobial
stewardship ward rounds, and a dedicated antimicrobial prescrip-
tion chart. The hospital pharmacy has utilized an electronic
medicine management system (JAC Medicines Management
software) since the year 2000; however, comprehensive data on
antimicrobial consumption rates by ward are not disseminated
routinely. The JAC software system manages and streamlines
procurement, stock keeping, dispensing, and distribution of
pharmaceuticals within the pharmacy, but the hospital does not
currently have access to the electronic prescribing JAC software
module.
Study design
From May 10, 2015 to November 11, 2015, data from inpatient
records and antimicrobial prescriptions were collected pro-
spectively on two wards (the PICU and a general paediatric
ward) for all children admitted for >48 h during a study to
establish the incidence of paediatric HAI (Dramowski et al.,
2016). This dataset (6-month antimicrobial prescription audit)
included drug name, dose, duration, and indication type (CAI,
HAI, or prophylaxis). Antiretrovirals, anti-TB drugs, and co-
trimoxazole prophylaxis for Pneumocystis jirovecii were not
included in the audit. For the same 6-month period and the same
two wards, data were extracted from the pharmacy electronic
medicine management system (JAC), including drug name, total
units dispensed, total consumption (in milligrams, grams, or
international units), and cost (in South African Rand). Observed
antimicrobial use was described using the prospectively collected
antimicrobial prescription audit data. Antimicrobial cost data were
derived from the pharmacy dispensing data. The two datasets
were compared to determine the variance between audit data
(observed use) and dispensing data and the feasibility of using the
pharmacy dispensing data for future surveillance of paediatric
antimicrobial use.
Study deﬁnitions
CAI included all infectious diseases that were acquired prior
to the current hospitalization episode. HAI included any
infection that was neither present nor incubating at the time
of hospital admission (National Healthcare Safety Network,
2013). Antimicrobial prophylaxis included the prescription of
antimicrobials for the purpose of preventing inpatient surgical
or medical infections (other than co-trimoxazole  prophylaxis for
Pneumocystis jirovecii, isoniazid prophylactic therapy, and antire-
troviral prophylaxis for the prevention of mother-to-child
transmission of HIV). ‘Patient-days’ was deﬁned as the sum of
all patient lengths of stay per ward per month. The antimicrobial
consumption or utilization rate was deﬁned as the total proportion
of patients over the study period who received one or more
antimicrobial drugs during their admission episode. Days of
therapy (DOT) was calculated for each antimicrobial agent as the
sum of all patient usage of that drug in the total number of days
received (Tadesse et al., 2017). For calculation of antimicrobial
costs, the currency conversion rate for South African Rand (ZAR)
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was used (1 USD = 11.89 ZAR).
Data handling and analysis, and ethical approval
The following indices were calculated for each ward using the
prescription audit data only (as the necessary variables were not
available from the dispensing data): (1) the antimicrobial
prescription prevalence rate; (2) the mean number of antimicro-
bials per patient admission episode; (3) the indication/s for
antimicrobial/s (CAI, HAI, prophylaxis); (4) the antimicrobial
spectrum prescribed (antibacterial, antifungal, antiviral, and the
proportional contribution of each drug to the overall antimicrobial
usage); (5) the length of hospital stay versus number of
antimicrobials prescribed. Antimicrobial costs were calculated
from the dispensing data. Audit data were compared with
dispensing data to calculate the variance in usage between
datasets. In some instances, children had more than one admission
episode to the selected wards during the study period; these
admission episodes were included using the patient’s current
weight, age, and prescription indication.
Continuous and categorical data were analyzed using the
Student t-test and Fisher’s exact test/Chi-square test, as appropri-
ate. Pearson’s correlation coefﬁcient was used to investigate the
relationship between length of hospital stay and the number of
antimicrobials prescribed. A p-value of <0.05 was considered
statistically signiﬁcant. Stata statistical software version 13.1
(StataCorp, USA) was used for the data analysis.
Ethical approval and a waiver of individual informed consent
was obtained from the Human Health Research Ethics Committee
of Stellenbosch University (Ref. No. S13/09/171).Table 1
Demographics of the study population (n = 703).
Paediatric ward (n = 4
1 antimicrobial
prescription
No antimicro
prescription
Proportion of patients prescribed 1
antimicrobial drug
415 (92%) 36 (8%) 
Total number of antimicrobials prescribed 904 NA 
Mean antimicrobials per patient, n (range) 2.2 (1–8) NA 
Sex, male 233 (56.1%) 22 (61.1%) 
Age in months, median (IQR) 5.5 (1.6–21.5) 27.4 (6.1–86
Age category 
Neonate (<28 days) 57 (13.7%) 0 (0%) 
Infant (29–364 days) 212 (51.1%) 13 (36.1%) 
Toddler (1–5 years) 104 (25.1%) 12 (33.3%) 
Child (>5 years) 42 (10.1%) 11 (30.6%) 
Weight in kilograms, median (IQR) 5.7 (3.7–9.4) 9.4 (5.8–15.7
HIV prevalence 
HIV-infected 25 (6.0%) 2 (5.5%) 
HIV-exposed uninfected 77 (18.6%) 5 (13.9%) 
HIV-negative 293 (70.6%) 28 (77.8%) 
HIV unknown 20 (4.8%) 1 (2.8%) 
Length of stay in days, mean (SD) 6 (4–9) 6 (3–9) 
Indication for antimicrobial/s 
Community-acquired infection 809/904 (89%) NA 
Healthcare-associated infection 94/904 (10%) 
Prophylaxisa 1/904 (0%) 
Outcome 
Discharged or transferred 412 (99.3%) 36 (100%) 
Died 3 (0.7%) 0 (0%) 
ICU, intensive care unit; NA, not applicable; IQR, interquartile range; SD, standard dev
a Prophylaxis included medical and surgical prophylaxis other than co-trimoxazole pro
prophylaxis for prevention of mother-to-child transmission of HIV.Results
A total of 703 patients were admitted during the study period:
451 to the general paediatric ward and 252 to the PICU (Table 1). Of
patients admitted to the ward, 415/451 (92%) were prescribed one
or more antimicrobials during their hospital stay; an average of 2.2
antimicrobials were prescribed per admission episode (range 0–8
antimicrobials). Overall on the ward, 904 antimicrobials were
prescribed, generating 4079 DOT and a usage rate of 1137 DOT/
1000 patient-days. Among patients admitted to the PICU, 233/252
(92%) were prescribed one or more antimicrobial drugs with an
average of 2.8 antimicrobials per patient (range 0–11). Overall, 662
antimicrobials were prescribed, generating 3810 DOT and a usage
rate of 1323 DOT/1000 patient-days. Younger patients (neonates
and infants) had signiﬁcantly higher antimicrobial usage rates than
older children, both on the ward and in the PICU. Patients in the
PICU were signiﬁcantly more likely to be prescribed an antimicro-
bial for HAI than patients on the ward (p < 0.001). As the number of
antimicrobials prescribed per patient increased, the mean duration
of stay increased signiﬁcantly for the population (Pearson
correlation coefﬁcient 0.360 (moderate correlation), p < 0.001)
(Figure 1a). For both ward and PICU combined (n = 703), patients
who died (n = 23) received signiﬁcantly more antimicrobials than
those who survived (median of 5 vs. 2 antimicrobials, respectively)
(Figure 1b).
Most antimicrobials were given parenterally (72% on the ward
and 87% in the PICU). The third-generation cephalosporins
(cefotaxime and ceftriaxone) were the most commonly prescribed
intravenous (IV) antimicrobials on the paediatric ward (833 DOT)
and in the PICU (436 DOT). On the ward, ampicillin (757 DOT) and
gentamicin (442 DOT) were the second and third most frequently51) Paediatric ICU (n = 252)
bial p-
Value
1 antimicrobial
prescription
No antimicrobial
prescription
p-Value
– 233 (92%) 19 (8%) –
– 662 NA –
– 2.8 (1–11) NA –
0.564 130 (55.8%) 12 (63.1%) 0.534
.4) <0.001 5.9 (2.2–21.5) 27.9 (10.0–47.5) 0.001
<0.001 0.015
25 (10.7%) 0 (0%)
125 (53.7%) 6 (31.6%)
59 (25.3%) 11 (57.9%)
24 (10.3%) 2 (10.5%)
) <0.001 6.5 (3.6–10.5) 9.8 (7.3–13.6) 0.036
0.815 0.05
24 (10.3%) 0 (0%)
31 (13.3%) 2 (10.5%)
164 (70.4%) 13 (68.4%)
14 (6.0%) 4 (21.1%)
0.437 9 (5–13) 3 (2–4) <0.001
– –
464/662 (70%) NA
191/662 (29%)
7/662 (1%)
0.609 0.183
213 (91.4%) 19 (100%)
20 (8.6%) 0 (0%)
iation; HIV, human immunodeﬁciency virus.
phylaxis for Pneumocystis jirovecii, isoniazid prophylactic therapy, and antiretroviral
Figure 1. (a) Total number of antimicrobials prescribed versus outcome of hospitalization. (b) Total number of antimicrobials prescribed versus length of hospitalization.
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and ganciclovir (383 DOT) were the second and third most
frequently prescribed IV antimicrobials (Figure 2a, b). Commonly
used oral antimicrobials on the ward were amoxicillin (489 DOT),
amoxicillin–clavulanic acid (271 DOT), and penicillin VK (81 DOT).
In the PICU, co-trimoxazole was the most commonly prescribed
oral antimicrobial (141 DOT), followed by amoxicillin–clavulanic
acid (129 DOT) and erythromycin (89 DOT) (Figure 2c, d).
CAI were the main indication for antimicrobial prescription
(89% on the ward, 70% in the PICU; p < 0.001) with ampicillin and
third-generation cephalosporins being the most common agents
prescribed for CAI (Figure 3a, c). Ertapenem and meropenem were
the most commonly prescribed antimicrobials for HAIs on the
ward and in the PICU (Figure 3b, d). Prophylactic antimicrobials
constituted a very small percentage of overall usage on the ward
and in the PICU (0.1% and 1.1%, respectively).Of the different antimicrobial classes, antibacterial agents were
most commonly used (94% on the ward and 81% in the PICU), with
antifungals and antivirals making up a small proportion of
antimicrobials used. However, in terms of days of therapy,
ganciclovir, aciclovir, and valganciclovir usage was substantial,
being the 4th, 11th, and 14th overall largest contributors to DOT in
the PICU. There was also a greater diversity of antimicrobials
prescribed in the PICU than on the ward.
Antimicrobial costs calculated from the pharmacy dispensing
data estimated a total antimicrobial spend on the general
paediatric ward of 67 541 ZAR (USD 5680) in total, equating to
162 ZAR (USD 13.69) per infected patient. In the PICU,
antimicrobial prescriptions totalled 210 484 ZAR (USD 17 702),
and 903 ZAR (USD 75.98) per infected patient. Ertapenem and
meropenem were the single largest contributor to antimicrobial
costs on the ward (43% of total costs) and in the PICU (30% of
Figure 2. (a) Total days of intravenous (IV) antimicrobial therapy on the paediatric ward. (b) Total days of intravenous (IV) antimicrobial therapy in the paediatric ICU. (c) Total
days of oral antimicrobial therapy on the paediatric ward. (d) Total days of oral antimicrobial therapy in the paediatric ICU.
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shown in Table 2.
The most commonly prescribed IV antimicrobials from the
prescription audits were compared with the volume of the same
antimicrobial agents dispensed according to the pharmacy data
(Table 3). For the general paediatric ward, with the exception of
amoxicillin–clavulanic acid and ertapenem, consumption
exceeded volumes dispensed by up to 2.8-fold. Conversely in
the PICU, a larger volume of antimicrobials was dispensed than was
actually consumed.
Discussion
These data represent one of the ﬁrst overviews of paediatric
antimicrobial use at a South African hospital. Very high rates of
antimicrobial use were documented both on the ward and in the
PICU, exceeding rates reported from most other paediatric
inpatient settings worldwide (Feleke et al., 2013; Grohskopf
et al., 2005; Amadeo et al., 2010; Gandra et al., 2017; De Luca
et al., 2016). In comparison to a German study of antimicrobial use
on general paediatric wards (reporting DOT of 483/1000 patient-
days) (Kreitmeyr et al., 2017), the general ward in the present study
utilized 1137 DOT/1000 patient-days. This substantially higher
usage may be ascribed to the inclusion of antivirals and antifungals
in this study, and the greater burden of infectious diseases among
the paediatric admissions. However, the antimicrobial usage data
are not dissimilar to those reported in the few published studies
from other African paediatric wards (Monteiro et al., 2017; Labi
et al., 2018; Fisher et al., 2009; Alemnew and Atnaﬁe, 2015). The
present study data support existing evidence that antimicrobial
use on the continent is substantial, highlighting the need for
greater surveillance of antimicrobial use and the implementation
of antimicrobial stewardship programmes in African hospitals.
In this Tygerberg Hospital cohort, it was possible to show a
signiﬁcant association between antimicrobial use and young age(every neonate had at least one antimicrobial prescribed),
highlighting the difﬁculty in excluding infectious diseases in
the neonate/young infant. Furthermore, an association between
longer length of stay and greater number of antimicrobials
prescribed was demonstrated, which probably reﬂects compli-
cated clinical disease course and the greater likelihood of HAI as
the length of hospital stay increases. Similarly, a signiﬁcant
association between antimicrobial use and outcome was shown,
with PICU patients who received antimicrobials having a crude
mortality rate of 8.6% versus no deaths among patients who did
not receive antimicrobials.
In the global ARPEC point prevalence study, gentamicin and
ceftriaxone were the most commonly prescribed  antimicrobials
among paediatric inpatients, whereas at the study institution,
third-generation cephalosporins, ampicillin, and gentamicin
were the most widely prescribed antimicrobials. For both the
ward and PICU, CAI was the most common indication for
receiving an antimicrobial/s: third-generation cephalosporins
(23% on the general ward and 19% in the PICU) and ampicillin
(25% on the general ward and 18% in the PICU) were most
commonly used. In a Ghanaian teaching hospital, third-
generation cephalosporins were commonly used for CAIs
(28%) (Labi et al., 2018).
For HAI, the study institution predominantly used carbape-
nems, namely meropenem (31% on the general ward and 34% in the
PICU) and ertapenem (39% on the general ward and 19% in the
PICU). As part of ongoing antimicrobial stewardship efforts, broad-
spectrum antimicrobial use for suspected HAI requires consultant
approval and a named-patient prescription to pharmacy for
authorization. This high carbapenem usage most likely reﬂects
the hospital guidelines in 2015 at the time of data collection.
Subsequently, the recommended empiric HAI treatment for ward
patients has changed to piperacillin–tazobactam and amikacin
(personal communication, Dr Heather Finlayson), which has led to
an increase in consumption of these antibiotics. Clinicians are
Figure 3. (a) Antimicrobials used for community-acquired infection on the paediatric ward (n = 809). (b) Antimicrobials used for healthcare-associated infection on the
paediatric ward (n = 94). (c) Antimicrobials used for community-acquired infection in the paediatric ICU (n = 464). (d) Antimicrobials used for healthcare-associated infection
in the paediatric ICU (n = 191).
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scription chart), to stop or de-escalate the empiric broad-spectrum
antimicrobial therapy after 72 h if the initial laboratory inves-
tigations for sepsis are negative. HAI as an indication for
antimicrobial prescription occurred more frequently in the PICU,
although this ﬁnding was not surprising given the severity of
illness, use of indwelling devices, and extended hospital stay of
populations in an ICU setting.Prophylaxis as an indication for antimicrobial use in the PICU
and on the ward was rare, reﬂecting the small number of paediatric
surgical patients included. A recent antimicrobial point prevalence
survey in a teaching hospital in Ghana showed a different
distribution of indications for antimicrobial therapy compared
to the study institution: 40% were for CAI, 21% for HAI, 34% for
surgical prophylaxis, and 5% for medical prophylaxis (this study
included both adult and paediatric medical and surgical wards).
Table 2
Total costs of antimicrobials utilized in the paediatric ward and ICU.
General paediatric ward Paediatric ICU
Antimicrobial Grams
used
Cost in ZAR per
gram
Cost in
ZAR
Cost in
USD
% of total
cost
Antimicrobial Grams
used
Cost in ZAR per
milligram
Cost in
ZAR
Cost in
USD
% of total
cost
Ertapenem 79 368 29 095 2447 43% Meropenem 470 132 62 114 5224 30%
Ampicillin 560 14 8056 678 12% Ertapenem 141 368 51 930 4367 25%
Amoxicillin 3750 1.9 7125 599 11% Ganciclovir 52 791 40 715 3424 19%
Aciclovir 25 (IV)
60 (PO)
235 (IV)
1.6 (PO)
5853 492 9% Aciclovir 100 (IV)
15 (PO)
235 (IV)
1.6 (PO)
23 542 1978 11%
Meropenem 30 132 4008 337 6% Ampicillin 506 14 7286 613 3%
Others – – 13 401 1127 20% Others – – 24 913 2095 12%
Total – – 67 541 5680 100% Total – – 210 484 17 702 100%
ICU, intensive care unit; ZAR, South African Rand; USD, United States Dollars; IV, intravenous; PO, oral.
Table 3
Variance between selected antimicrobials: pharmacy dispensed versus ward/PICU consumed.
Antimicrobial Ward dispensed
(grams)
Ward consumed
(grams)
Variancea PICU dispensed
(grams)
PICU consumed
(grams)
Variancea
Meropenem 30 67 0.4 470 289 1.6
Ertapenem 79 48 1.6 141 66 2.1
Vancomycin 3 10 0.3 170 77 2.2
Cefotaxime 262 284 0.9 180 152 1.2
Ceftriaxone 270 345 0.8 234 252 0.9
Ampicillin 560 739 0.8 506 575 0.9
Amoxicillin–clavulanic acid 24 22 1.1 174 62 2.8
PICU, paediatric intensive care unit.
a Variance was calculated as dispensed grams/consumed grams  100.
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by ward of origin: the antimicrobial cost per infected patient was
ﬁve-fold higher for PICU patients (13.69 vs. 75.98 USD per infected
patient). There are several potential explanations for the cost
differential: PICU patients had higher rates of parenteral drug use,
higher rates of HAI (with greater use of carbapenems), extended
lengths of stay, and greater use of antivirals. However, an
additional factor contributing to this cost calculation may have
been overestimation of the volume of antimicrobials dispensed by
the pharmacy. In high-income countries, ongoing analysis of drug
utilization rates and prescribing trends has been used successfully
by hospital antimicrobial stewardship programmes (Reddy et al.,
2015; Araujo da Silva et al., 2017; Smith et al., 2015) to lower the
cost of and reduce unnecessary antimicrobial use.
Lastly, it was aimed to determine whether pharmacy dispensing
data accurately reﬂect antimicrobial consumption on paediatric
wards, and whether dispensing data could be used as a ‘proxy’ for
antimicrobial audits. Comparing the dispensed and the audit data,
a substantial variation between the volumes of selected intrave-
nous antimicrobials dispensed and the actual volumes given was
observed. In general, the dispensing data recorded similar volumes
of antimicrobials used for the treatment of CAI on the ward, e.g.,
ampicillin, amoxicillin–clavulanic acid, and third-generation
cephalosporins. However, the pharmacy dispensing data under-
estimated antimicrobial use for restricted antimicrobials used for
the treatment of HAI on the ward (i.e., more consumed than
dispensed for meropenem, ertapenem, and vancomycin). The most
likely explanation for this ﬁnding is that many wards keep
commonly used antimicrobials as ward stock; therefore pharmacy
orders do not necessarily reﬂect real-time use. In addition,
interviews of nursing staff who administer antimicrobials on the
wards conﬁrmed that sharing of multi-dose vials between patients
was common practice and that patients transferred between wards
may be transferred with their dispensed antimicrobials, obviating
the need to order stock from the pharmacy. In addition, some
patients received their ﬁrst doses of antimicrobials in the acuteadmission ward prior to transfer to the general paediatric ward or
PICU, which may have also had a minor effect on estimating total
antimicrobial volume consumed.
Conversely, the pharmacy dispensed greater volumes of
antimicrobials to the PICU than were given according to the audit
data, except for ampicillin and the third-generation cephalospor-
ins, which correlated well with observed use. It was subsequently
discovered that the pharmacy dispensing data combined orders
from both the PICU and the adjacent neonatal intensive and high-
care units (NICU), which is likely the main reason for the higher
dispensed volumes.
Another ﬁnding when reviewing the pharmacy dispensing data
was that broad-spectrum, restricted antimicrobials were com-
monly issued as ‘ward stock’, making it impossible to link
antimicrobial use with a particular patient and indication. In view
of these ﬁndings, it is clear that the pharmacy dispensing data
capturing system would require reﬁnements to improve its
usefulness as a tool for tracking antimicrobial consumption and
ward stock on the paediatric wards and PICU at the study
institution. It should be noted that the pharmacy electronic
medicine management system was originally implemented to
manage the procurement and ﬁnances rather than to track
antimicrobial consumption. In the interim, repeated point preva-
lence surveys and antimicrobial usage audits should be continued
in order to track the impact of antimicrobial stewardship
programmes on the wards. However, with some local system
adaptations, pharmacy dispensing data could represent a viable
method for antimicrobial consumption tracking in the future.
Electronic prescribing, however, would be ideal to accurately
assess antimicrobial usage.
The strengths of this study are the inclusion of a large inpatient
population from two diverse wards at a large South African
children’s hospital. Limitations of the study are the exclusion of
patients who were admitted for less than 48 h, which may have led
to either over- or underestimation of the antimicrobial use, and the
lack of data on discharge prescriptions (which led to an
L.R. Koopmans et al. / International Journal of Infectious Diseases 74 (2018) 16–23 23underestimation of the total days of antimicrobial use, as children
could take antimicrobials home or ﬁnish the course in another
hospital). Although the study ﬁndings are not generalizable to all
hospitals in Africa, the data can inform other paediatric centres
that are developing antimicrobial consumption surveillance
programmes.
In conclusion, antimicrobial usage rates at Tygerberg Hospital
were very high compared to developed country estimates, but
comparable to data from the African continent. Antimicrobial
consumption as measured by the pharmacy dispensing data,
differed from the antimicrobial use observed in prescription audits,
but with some system adaptations, represents a feasible method
for antimicrobial consumption tracking in the future.
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